Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > Alzheimer's Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs.

TitleAlzheimer's Disease Can Be Spared by Nonsteroidal Anti-Inflammatory Drugs.
Publication TypeJournal Article
Year of Publication2018
AuthorsMcGeer, PL, Guo, JPing, Lee, M, Kennedy, K, McGeer, EG
JournalJ Alzheimers Dis
Volume62
Issue3
Pagination1219-1222
Date Published2018
ISSN1875-8908
Abstract

Alzheimer's disease (AD) is characterized by deposits of amyloid-β protein (Aβ) in brain which become foci of inflammation. Neurons are destroyed by this inflammatory process, leading to the cognitive deficits which define AD clinical onset. Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) can ameliorate this destructive process if they are started well before clinical signs develop. Biomarker studies indicate that the disease process starts at least a decade before cognitive deficits appear. This pre-clinical onset explains the NSAID effect. It also opens a window of opportunity for preventive treatment that can be met with a simple diagnostic test. Salivary levels of Aβ42 may fulfill that need. They can be measured by a simple ELISA test we have developed using commercially available reagents. By this ELISA test, normal controls, who are not at risk for AD, have levels of Aβ42 close to 20 pg/ml. AD cases, as well as high level controls, secrete levels in the range of 40-85 pg/ml. Widespread application of this test to detect high level controls, followed by NSAID consumption, could substantially reduce the prevalence of AD.

DOI10.3233/JAD-170706
Alternate JournalJ. Alzheimers Dis.
PubMed ID29103042
PubMed Central IDPMC5870017
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

Source URL: https://www.j-alz.com/content/alzheimers-disease-can-be-spared-nonsteroidal-anti-inflammatory-drugs